NCT04052880 : Phase 2 - SubQ Dara + Dose-Atten. Bortezomib, Lenalidomide, Dex New MM >70 years
Official Title: A Phase 2 Study of Subcutaneous Daratumumab in Combination With Dose-Attenuated Bortezomib, Lenalidomide, and...
Dec 30, 2019
Â
2020 SOHO Annual meeting : Eighth annual meeting of the Society of Hematologic Oncology
The eighth annual meeting of the Society of Hematologic Oncology (SOHO 2020) is scheduled for September 9–12, 2020. Organized by its...
Dec 28, 2019
Â
NCT04181827: Phase 3 -Cilta-cel vs Pom/Bort/Dex or Dara/Pom/Dex in relpsd. len ref MM CARTITUDE 4
CARTITUDE-4 Ciltacabtagene Autoleucel A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA),...
Dec 28, 2019
Â
NCT04196491: Phase 1 - Evaluate the Safety of bb2121 in High Risk, New Myeloma (NDMM) (KarMMa-4)
KarMMa-4 A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4) Relapsed...
Dec 27, 2019
Â
FDA Approved NDMM Transplant Eligible: Daratumumab + Bortezomib, Thalidomide and Dexamethasone
On September 26, 2019, the Food and Drug Administration approved daratumumab (DARZALEX, Janssen) for adult patients with multiple myeloma...
Dec 25, 2019
Â
FDA Approved for NDMM Transp. Ineligible: Daratumumab + Lenalidomide & Dexamethasone
On June 27, 2019, the Food and Drug Administration approved daratumumab (DARZALEX, Janssen Biotech, Inc.) in combination with...
Dec 25, 2019
Â
NCT03984097: Phase 1: A Study to Evaluate Subcutaneous TAK-079 Added to Standard Regimens NDMM
NCT03984097: Phase 1: A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed...
Dec 21, 2019
Â
American Cancer Society - What is Multiple Myeloma?
American Cancer Society - What is Multiple Myeloma? What is Multiple Myeloma? If you have multiple myeloma or are close to someone who...
Dec 21, 2019
Â
The MAMMOTH study: Monoclonal Antibodies in Multiple Myeloma: Outcomes after Therapy Failure
MAMMOTH study Multicenter, retrospective study to investigate the natural history and outcomes of patients with MM refractory to CD38...
Dec 20, 2019
Â
NCT03997968: Phase 1/2: A Phase 1/2 Study of CYT-0851, Oral RAD51 Inhibitor, in B-Cell Malignancies
NCT03997968: Phase 1/2: A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors A Phase...
Dec 20, 2019
Â
NCT04131309: Phase 2: EMN 22 - Daratumumab Monotherapy in Stage 3B Light Chain (AL) Amyloidosis
NCT04131309: Phase 2: A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis...
Dec 19, 2019
Â
NCT04036461: Phase 1 - A Study of CC-99712, a BCMA Antibody-Drug Conjugate in relapsed MM
Study CC-99712-MM-001 This is an open-label, Phase 1, dose escalation (Part A) and expansion (Part B), First-in-Human (FIH) clinical...
Dec 19, 2019
Â
NCT04045795: Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT04045795: Phase 1: Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) NCT04045795:...
Dec 19, 2019
Â
NCT04096066: Phase 3: EMN 20 - A Trial That Compare Two Treatments TIE - NDMM - KRd Vs Rd
NCT04096066: Phase 3: A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant (KRd vs Rd)...
Dec 19, 2019
Â
NCT04133636: Phase 2 - Study of JNJ-68284528, CAR-T Therapy Directed Against BCMA in MM -CARTITUDE-2
CARTITUDE-2 Ciltacabtagene Autoleuce A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell...
Dec 19, 2019
Â
FDA Approved for RRMM: Xpovio (selinexor) tablets + Dexamethasone
On July 3, 2019, the Food and Drug Administration granted accelerated approval to selinexor (XPOVIO, Karyopharm Therapeutics) in...
Dec 18, 2019
Â
NCT03901963: Phase 3 - Dara + Len vs Len as Maint. in New Myeloma +MRD after frontline ASCT (AURIGA)
AURIGA Study A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly...
Dec 18, 2019
Â
Showering While You Have a Central Venous Catheter | Memorial Sloan Kettering
Showering While You Have a Central Venous Catheter | Memorial Sloan Kettering
Dec 14, 2019
Â
NCT04144387: IFM2017 Evaluation of the Impact of the Update SMM Criteria on the Natural History SMM
IFM 2017-04 - CARRISMM NCT04144387: Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New...
Dec 14, 2019
Â